Humana Inc. has announced the expansion of its board of directors and the election of two new independent directors, Frederick J. Crawford and Paul J. Smith, effective July 28, 2026. The board increased its authorized size from eleven to thirteen members to accommodate the appointments. Both directors have been determined to meet New York Stock Exchange independence standards and will participate in the company's standard director compensation program.

Key Points

  • NYSE: HUM
  • Humana's board expanded from eleven to thirteen authorized directors on July 28, 2026
  • Frederick J. Crawford and Paul J. Smith elected as independent directors effective July 28, 2026
  • Both directors qualify as independent under NYSE standards and will receive restricted stock units under the company's director compensation program

Board Expansion Increases Authorized Director Count

Humana Inc. disclosed that its Board of Directors voted to expand the number of authorized board seats from eleven to thirteen members on July 28, 2026. This expansion reflects the company's strategic decision to bring additional governance capacity and expertise to its oversight functions during a period of operational and strategic importance. The filing indicates that this structural change was implemented simultaneously with the election of the two new directors, establishing the expanded board framework.

The increase in authorized director positions represents a formal governance adjustment that allows the board to accommodate future recruitment of qualified candidates while maintaining appropriate oversight of the company's healthcare operations and strategy. The announcement of the board expansion occurred on July 29, 2026, through a press release distributed to investors and stakeholders.

Election of Frederick J. Crawford as Independent Director

Frederick J. Crawford was elected to the Humana board of directors effective July 28, 2026. The Board of Directors determined that Crawford meets the New York Stock Exchange's director independence standards, qualifying him as an independent director. The filing states that Crawford was elected without any disclosed arrangements or special agreements that would have influenced his selection to the board.

Crawford will participate in Humana's standard director compensation program. As part of his appointment, Crawford will be granted restricted stock units (RSUs) consistent with the compensation structure outlined in the company's 2026 proxy statement filed on March 6, 2026. The filing does not provide biographical details or professional background information regarding Crawford beyond his independent status classification.

Election of Paul J. Smith as Independent Director

Paul J. Smith was elected to the Humana board of directors effective July 28, 2026, concurrent with Crawford's election. Like Crawford, Smith has been determined by the Board of Directors to qualify as an independent director under New York Stock Exchange standards. The filing indicates that no arrangements or transactions exist between Smith and any other party that would have factored into his board selection.

Smith will receive compensation in accordance with Humana's director compensation program, including the grant of restricted stock units upon his election to the board. The compensation components were previously disclosed in the company's proxy statement relating to the 2026 Annual Meeting of Stockholders. The specific biographical information and professional credentials of Smith are not detailed in the current disclosure.

Director Independence and NYSE Compliance Standards

Both Crawford and Smith have been certified by the Board of Directors as meeting the New York Stock Exchange's director independence standards. These standards establish specific criteria regarding relationships, transactions, and financial interests that determine whether a director can be classified as independent. The filing confirms that both newly elected directors satisfy these requirements, enhancing the independent oversight capacity of the board.

The company's determination of director independence is a key governance factor that affects board committee assignments, leadership roles, and overall board composition ratios. The filing notes that the Board has not yet made determinations regarding committee assignments for Crawford and Smith, suggesting that such appointments may be announced at a later date as the board evaluates committee structure and expertise needs.

Director Compensation Structure and Restricted Stock Units

Humana's director compensation program provides a standardized framework for compensating board members who are elected to serve. The filing states that both Crawford and Smith will be compensated in accordance with this established program, which was disclosed in detail in the company's proxy statement filed on March 6, 2026. As part of their compensation, each new director will receive restricted stock units (RSUs) granted in connection with their election to the board.

The use of RSUs ties director compensation to company performance and shareholder value, aligning the financial interests of directors with those of investors. The filing does not specify the number of RSUs to be granted, the vesting schedule, or the specific value of the grants, indicating that such details may be provided in subsequent disclosures or in accordance with the company's standard compensation protocols already disclosed to shareholders.

Absence of Material Conflicts or Related-Party Transactions

The filing explicitly discloses that no arrangements exist between Crawford or Smith and any other person that would have influenced their election as directors. Additionally, the company states that no transactions exist between Humana or its subsidiaries and either Crawford or Smith in which they have a material interest. This representation provides assurance to investors that the board expansion does not involve undisclosed conflicts of interest or related-party considerations.

This disclosure is significant because it establishes that the directors were elected based on their qualifications and the board's strategic needs rather than through any special arrangements or existing business relationships. Such transparency regarding the absence of conflicts strengthens the credibility of the board's independence determinations and aligns with corporate governance best practices.

Timing and Announcement of Director Elections

The Board of Directors voted on July 28, 2026 to expand the authorized board size and elect both Crawford and Smith, with the changes becoming effective on the same date. On July 29, 2026, the company issued a press release announcing these board changes to the public and investment community. The filing incorporates the press release by reference and identifies it as Exhibit 99.1 to the current disclosure.

The one-day lag between the board action and public announcement reflects standard corporate practice for coordinating internal governance decisions with external communications. The immediate disclosure of board changes through a current report demonstrates the company's commitment to timely transparency regarding material governance matters.

Future Committee Assignments and Board Structure

The filing explicitly states that no determination has yet been made regarding the appointment of Crawford or Smith to any committees of the Board. This indicates that the company is deferring committee assignment decisions for a later date, potentially pending a more comprehensive review of committee composition, expertise requirements, and workload distribution. Committee assignments typically occur following formal board election and may be coordinated with the company's annual meeting or at the board's next appropriate meeting.

The delay in committee appointments is a standard governance practice that allows the board to assess how the newly expanded composition affects existing committee structures and to ensure optimal alignment of director expertise with committee responsibilities. Investors may look for subsequent disclosures regarding these assignments as part of the company's ongoing governance communications.

Impact on Humana's Governance and Oversight Framework

The addition of two independent directors to Humana's board increases the total number of independent directors and enhances the board's capacity for oversight, committee work, and strategic deliberation. With the board expanding from eleven to thirteen seats, the company is positioned to address increased governance responsibilities and bring diverse expertise to bear on company strategy and operations. The selection of directors meeting NYSE independence standards ensures that a substantial portion of the board operates without conflicts of interest.

Investors in Humana have a continued interest in monitoring the company's governance structure, as board composition and independence metrics are factors in evaluating corporate governance quality. The expansion and the subsequent committee assignments will contribute to the overall governance profile that investors assess when making decisions about the company's management and leadership.